The human milk oligosaccharide 2′-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestine

Misty Good1,2, Chhinder P. Sodhi3,4, Yukihiro Yamaguchi3,4, Hongpeng Jia3,4, Peng Lu3,4, William B. Fulton3,4, Laura Y. Martin3,4, Thomas Prindle Jr3,4, Diego F. Nino3,4, Qinjie Zhou3,4, Congrong Ma1,2, John A. Ozolek5,6, Rachael H. Buck7, Karen C. Goehring7 and David J. Hackam3,4*

© The Authors 2016

Abstract

Necrotising enterocolitis (NEC) is a common disease in premature infants characterised by intestinal ischaemia and necrosis. The only effective preventative strategy against NEC is the administration of breast milk, although the protective mechanisms remain unknown. We hypothesise that an abundant human milk oligosaccharide (HMO) in breast milk, 2′-fucosyllactose (2′FL), protects against NEC by enhancing intestinal mucosal blood flow, and we sought to determine the mechanisms underlying this protection. Administration of HMO-2′FL protected against NEC in neonatal wild-type mice, resulted in a decrease in pro-inflammatory markers and preserved the small intestinal mucosal architecture. These protective effects occurred via restoration of intestinal perfusion through up-regulation of the vasodilatory molecule endothelial nitric oxide synthase (eNOS), as administration of HMO-2′FL to eNOS-deficient mice or to mice that received eNOS inhibitors did not protect against NEC, and by 16S analysis HMO-2′FL affected the microbiota of the neonatal mouse gut, although these changes do not seem to be the primary mechanism of protection. Induction of eNOS by HMO-2′FL was also observed in cultured endothelial cells, providing a link between eNOS and HMO in the endothelium. These data demonstrate that HMO-2′FL protects against NEC in part through maintaining mesenteric perfusion via increased eNOS expression, and suggest that the 2′FL found in human milk may be mediating some of the protective benefits of breast milk in the clinical setting against NEC.

Key words: Necrotising enterocolitis; Human milk oligosaccharides; 2′-Fucosyllactose; Endothelial nitric oxide synthase; Breast milk

Necrotising enterocolitis (NEC) is a serious cause of morbidity and mortality in premature infants, and is a major public health concern due to the increasing number of premature infants1. NEC is characterised by the sudden onset of ischaemia and necrosis in the small intestine typically, but can occur in the colon, affecting up to 12% of premature infants, and has a mortality overall of up to 40%1–3, in part because current treatment options are limited to gut rest, broad-spectrum antibiotics and surgical resection of necrotic bowel4. NEC is a gastrointestinal disease in its early stages, but quickly becomes a systemic disease, manifest by cardiorespiratory collapse and signs of systemic sepsis1. Although the precise causes of NEC remain incompletely understood, our current understanding of the disease identifies a critical link between the administration of enteral formula and its development, as demonstrated by the finding that infants who are fed breast milk are largely protected from NEC development5–8.

In seeking to understand the mechanisms leading to NEC development, we9–12 as well as others13 have identified a critical role of the lipopolysaccharide (LPS) receptor toll-like receptor 4 (TLR4) in its pathogenesis. In a series of studies summarised in this recent review14, we and others have shown

Abbreviations: 2′FL, 2′-fucosyllactose; eNOS, endothelial nitric oxide synthase; HMO, human milk oligosaccharide; LPS, lipopolysaccharide; NEC, necrotising enterocolitis; TLR4, toll-like receptor 4.

* Corresponding author: D. J. Hackam, fax +1 410 502 5314, email dhackam1@jhmi.edu
that TLR4 activation in the intestinal epithelium leads to the loss of enterocytes through apoptosis\(^{12,15,16}\), followed by delayed repair through inhibition of migration and TLR4-mediated loss of intestinal stem cells\(^{17}\). These factors lead to the translocation of bacteria and LPS into the circulation where endothelial TLR4 activation occurs, resulting in a loss of endothelial nitric oxide synthase (eNOS), which leads to impaired perfusion and the development of experimental NEC\(^{18}\).

Several groups have sought to identify potential components of breast milk that could be responsible for exerting the protection against NEC in premature infants\(^{12,16-22}\), and many of these studies have shed light on the beneficial activities of human milk oligosaccharides (HMO)\(^{22-30}\). HMO are complex glycans that are abundant in human breast milk and not present in infant formula\(^23\) and have beneficial effects on the intestine. There are various pathways by which HMO exert their protective effects on the gut, including selective consumption by protective gut microbes\(^{20}\), as well as by binding to and thus preventing the adherence of bacteria to the intestinal epithelium\(^{31}\). HMO have also been shown to be absorbed into the circulation and excreted into the urine, suggesting that these molecules could also exert systemic effects\(^{32,33}\), and thus may play a protective role against a disease such as NEC, which has both intestinal and systemic components\(^1\). Importantly, there has been no mechanism that links the potential benefits of HMO against NEC – a disease with largely systemic manifestations and not reliably linked to a particular microbe.

In the current study, we seek to evaluate the role – if any – of an abundant HMO found in breast milk – namely, 2′-fucosyllactose (HMO-2FL) – in the protection against experimental NEC. To do so, we now focus on our recent observation that TLR4 plays a critical role in NEC development through its ability to modulate intestinal perfusion via eNOS expression as described above\(^{18}\). We specifically hypothesise that administration of HMO-2FL will reduce the incidence and severity of NEC in newborn mice through effects on mesenteric perfusion via eNOS regulation.

### Methods

#### Statement of ethics

The described animal experiments in this study were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal protocols were approved by the University of Pittsburgh’s Animal Care and Use Committee (protocol 12040382) and Johns Hopkins University (protocol M014M362).

#### Cells, materials, mice and reagents

LPS (Escherichia coli 0111:B4 purified by gel filtration chromatography, \(\geq 99\%\) pure) was obtained from Sigma-Aldrich. eNOS inhibitors – N\(^5\)-(1-iminoethyl)-L-carnitine dihydrochloride (L-NIO) and diphenyleuclidonium chloride (DPI) – were obtained from Santa Cruz Biotechnology. The following antibodies were obtained: eNOS (Enzo Life Sciences) and platelet endothelial cell adhesion molecule 1 (PECAM-1; BD Biosciences). The fluorescein-labelled *Lycopersicon esculentum* (tomato) lectin (Vector Laboratories) was used as a tracer of intestinal perfusion\(^{18}\). C57BL/6 and eNOS\(^{-/-}\) (B6-129P2-Nos3tm1Unc/J) mice were obtained from the Jackson Laboratory.

HMO-2FL was produced through a proprietary fermentation process (Kyowa Hakko Bio Co. Ltd). Purity (95-3\%) was established by high-performance ion chromatography with pulsed amperometric detection using relative peak area comparisons. Endotolxin level (0-375 EU/mg) was estimated by limulus assay (limulus amebocyte lysate QCL-1000; Lonza).

The cell line HUV-EC-C (HUVEC) (ATCC® CRL-1730\(^{39}\)) was obtained from American Type Culture Collection (ATCC) and maintained in endothelial cell basal medium (Cell Applications, Inc.) with low serum growth supplement (Thermo Fisher) at 37°C with 5% CO\(_2\). Where indicated, cells were treated with HMO-2FL (dose 100 mg/ml) 1 h before LPS administration (dose 1 mg/ml), and the induction of TLR4-mediated pro-inflammatory cytokines and eNOS expression were measured by quantitative real-time PCR (qRT-PCR) 6 h after administration of LPS. Immunohistochemistry and immunofluorescence were performed as described by Afrazi et al\(^{33}\) and evaluated using a Nikon AZ-C2* confocal microscope (Nikon Instruments). SDS-PAGE and qRT-PCR were performed as described by Good et al\(^{12}\).

### Induction of necrotising enterocolitis in neonatal mice

All animal experiments were approved by the University of Pittsburgh Animal Care and Use Committee. Experimental NEC was induced in 7–10-d-old mice as previously described\(^{10,34}\).

In brief, we used formula gavage (Similac Advance infant formula (Abbott Nutrition):Esbilac (PetAg) canine milk replacer in a 2:1 ratio at a dose of 50 µl NEC formula/g body weight) five times/d, which was supplemented with enteric bacteria obtained from an infant with severe NEC as described in Good et al\(^{35}\) to simulate the dysbiosis seen in human NEC. As both the infant formula and the puppy milk replacer are commercially available, a brief description of each component of the NEC formula is as follows. Similac Advance contains the following ingredients: water, non-fat milk, lactose, high oleic safflower oil, soya oil, coconut oil, galactooligosaccharides and whey protein concentrate. Less than 0.5% of C. cohnii oil, M. Alpina oil, β-carotene, lutein, lycopene, ascorbic acid, soy lecithin, monoglycerides, potassium citrate, calcium carbonate, potassium chloride, magnesium chloride, choline chloride, choline bitartrate, taurine, m-inositol, calcium phosphate, zinc sulphate, magnesium sulphate, dα-tocopheryl acetate, niacinamide, calcium pantothenate, L-carnitine, vitamin A palmitate, cupric sulphate, thiamine chloride hydrochloride, riboflavin, pyridoxine hydrochloride, folic acid, manganese sulphate, phylloquinone, biotin, sodium selenite, vitamin D₃, cyancobalamin, salt, potassium hydroxide and nucleotides (AMP, cytidine 5′-monophosphate, disodium GMP, disodium uridine 5′-monophosphate). Esbilac canine milk replacer contains water, condensed, skimmed milk, soya bean oil, sodium caseinate, cream, calcium caseinate, L-methionine, L-arginine, calcium carbonate, choline chloride, lecithin, magnesium sulphate, potassium chloride, monopotassium phosphate, salt, tricalcium phosphate, carrageenan, dipotassium phosphate, dicalcium phosphate, ascorbic acid,
ferrous sulphate, sodium hydroxide, zinc sulphate, vitamin A supplement, vitamin E supplement, niacin supplement, calcium pantothenate, copper sulphate, multivitamins, thiamine hydrochloride, pyridoxine hydrochloride, riboflavin, manganese sulphate, vitamin D₃ supplement, potassium citrate, potassium iodide, folic acid, vitamin B₁₂ supplement and biotin.

In addition to the formula used to induce NEC, mice were also subjected to 10 min of hypoxia (5% O₂, 95% N₂) via a chamber (Billups-Rothenberg) twice a day for 4 d. Where indicated, mice were supplemented with HMO-2 FL (5 mg/ml of formula, 0.25 mg/g body weight, once daily). The eNOS inhibitor DPI was dissolved in water–dimethyl sulfoxide (DMSO) (10:90), and a 25 mM stock was prepared of which 2 µl was added to each ml of NEC formula with each feeding as indicated. A 50-µl stock of L-NIO was made with water and 1 µl was added to each ml of NEC formula with each feeding.

**Necrotising enterocolitis severity assessment**

Mouse terminal ileal sections were assessed by histology for the degree of mucosal injury according to our previously published scoring system from 0 (normal) to 3 (severe injury)(36), gross morphology, weight loss and by the expressions of β-diversity were evaluated using the Mann–Whitney U test.

**Assessment of intestinal perfusion in neonatal mice**

In mice in which experimental NEC was induced, intestinal perfusion was assessed as previously described in the study by Yazji et al. (18). In brief, neonatal mice were intra-cardiacally injected with the fluorescently labelled tomato lectin (1 mg/ml, dose 5 µl/g body weight) for 5 min before euthanasia and intestinal harvest. Terminal ilea were co-stained with PECAM-1, an endothelial cell marker, and whole mounts were evaluated for PECAM-1 and tomato lectin fluorescent emission via confocal microscopy (Nikon AZ-C2™ confocal microscope). The quantification of the perfusion (villous perfusion index) was assessed as done previously (18). In brief, the sum total of tomato lectin fluorescence divided by the total volume of the mucosal vasculature is expressed as a percentage.

**Measurement of nitric oxide within the intestine**

Nitric oxide was measured within the intestine of mice in the indicated treatment groups using the OxiSelect™ In Vitro Nitric Oxide (Nitrite/Nitrate) Assay Kit (Cell Biolabs, Inc.) according to the manufacturer’s instructions.

**16S ribosomal RNA amplicon sequence analysis**

Raw paired-end reads output by the MiSeq platform was merged into consensus fragments by FLASH (37) and subsequently filtered for quality (maximum error rate 1%) and length (minimum 200 bp) using Trimmomatic (38) and Quantitative Insights into Microbial Ecology (QIIME)(39, 40). Spurious hits to the PhiX control genome were identified using Nucleotide Basic Local Alignment Search Tool (BLASTN) and removed. Passing sequences were trimmed of primers, evaluated for chimeras with UCLUST (de novo mode)(41) and screened for mouse-associated contaminants using Bowtie² (42) followed by a more sensitive BLASTN search against the Greengenes 16S database (43). Chloroplast and mitochondrial contaminants were detected and filtered using the Ribosomal Database Project classifier (44) with a confidence threshold of 80%. High-quality 16S sequences were assigned to operational taxonomic units (OTU) with Pearson’s ρ coefficient between these two species and all other OTU. Those OTU with Pearson’s ρ > 0.2 for both species were removed. We further removed low-abundance contaminants on the basis of taxa identified by Salter et al. (45). To normalise across samples, 16S profiles were subsampled to 1124 sequences per sample before downstream statistical comparisons. Differentially abundant taxa were detected using the negative binomial test with P-value correction using the false discovery rate (46, 47). β-Diversity calculations and principal coordinate analysis (PCoA) was performed using QIIME (39, 40). Differences in β-diversity were evaluated using the Mann–Whitney U test.

**Statistical analysis**

In our experimental NEC experiments, each mouse represents an individual symbol on a graph. Because of different numbers of pups randomised to each group, the numbers may vary between data sets, but each is shown in the relevant data set, and statistical analysis was performed using ANOVA for multiple groups or Student’s t test for paired groups using PRISM version 6.0 (GraphPad). Statistical significance was accepted at P < 0.05.

**Quantitative real-time PCR**

Quantitative real-time PCR was performed as previously described using the Bio-Rad CFX96 Real-Time System (Bio-Rad) (35) using the primers listed in Table 1 relative to the housekeeping gene ribosomal protein large, P0 (RPL0).

**Results**

**Necrotising enterocolitis severity in mice is reduced by the addition of the human milk oligosaccharide 2′-fucosyllactose to the formula**

As shown in Fig. 1, animals subjected to this experimental model developed gross evidence of small intestinal ischaemia, pneumonia intestinalis and inflammation (Fig. 1(a)), as well as histological evidence of mucosal destruction and inflammatory influx (Fig. 1(b)), compared with breast-fed controls. Importantly, the administration of HMO-2 FL (0.25 mg/g body weight once daily during the model) significantly reduced the severity of NEC as compared with mice that were administered standard NEC formula, as was determined by assessment of the degree of gross and microscopic intestinal mucosal injury (Fig. 1(a) and (b)), preservation of daily weights (Fig. 1(c)), mucosal severity score
In order to determine the mechanisms by which HMO-2FL could protect against the development of NEC, we next turned our attention to the effects of HMO-2FL on the potential regulation of eNOS-mediated mesenteric micro-angiography in mice that underwent experimental NEC. To do so, we first assessed the degree of mesenteric perfusion in the mouse model of experimental NEC in the presence or absence of HMO-2FL supplementation to the formula. As shown in Fig. 4, the intestinal perfusion in mice that were FF was significantly reduced compared with breast-fed controls, consistent with our previous findings. Importantly, the addition of HMO-2FL restored perfusion to levels comparable with that of mice that were breast-fed on each day of the model, as observed in Fig. 4(a) and quantified in Fig. 4(b). The improvement in perfusion corresponded to a pink and healthy appearing intestine in breast-fed mice as compared with the dusky bowel seen in NEC, which was reversed in the presence of HMO-2FL towards a healthy, pink and perfused appearance. Taken together, these findings illustrate that HMO-2FL restores intestinal perfusion in NEC. We next sought to explore the potential mechanisms involved and focused on the effects of the vasodilatory molecule eNOS.

Human milk oligosaccharide 2′-fucosyllactose maintains the expression of endothelial nitric oxide synthase in necrotising enterocolitis, and thus restores intestinal perfusion in neonatal mice

Having now shown that HMO-2FL restores mesenteric perfusion in NEC, we next sought to investigate the possibility that HMO-2FL may affect the expression of eNOS. To do so, we assessed the expression of eNOS in the intestine of mice with and without NEC in the presence or absence of HMO-2FL. As shown in Fig. 4, the expression of eNOS in the intestine was significantly reduced in FF mice compared with breast-fed control mice, and this was restored after HMO-2FL induction (Fig. 4(c) and (d (i, ii))). The finding that HMO-2FL could restore the expression of eNOS in the newborn gut in the setting of NEC raises the intriguing possibility that perhaps the protection against NEC by HMO-2FL occurs via induction of eNOS expression. To assess this directly, we next utilised two approaches to inhibit eNOS – the use of pharmacological inhibitors and the use of eNOS knockout mice – and sought to determine whether HMO-2FL could still protect against NEC development under conditions of eNOS inhibition. As shown in Fig. 5, we next treated mice with eNOS inhibitors L-NIO dihydrochloride and DPI. Importantly, under conditions of eNOS inhibition (verification in the online Supplementary Fig. S1(a)),

- **Table 1. List of primers**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Species</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
<th>Amplicon size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RPLO</td>
<td>Mouse/human</td>
<td>GCCGACCTGGAGACTCAACT</td>
<td>CCATCAGGCCACACGCTTC</td>
<td>143</td>
</tr>
<tr>
<td>IL-6</td>
<td>Mouse</td>
<td>GGCTAAGGACCAAGACCATCCAA</td>
<td>TCTGACCACATGTGGAGATGCAA</td>
<td>138</td>
</tr>
<tr>
<td>TLR4</td>
<td>Mouse</td>
<td>TTATTCAGAAGGGGTTTGGTG</td>
<td>CAGAGATTGGTCCTCCATT</td>
<td>186</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Mouse</td>
<td>AGTGGTGTGACCCAGCAAATACCCA</td>
<td>TGTCCTGACGCTGTGGTTTCCCA</td>
<td>175</td>
</tr>
<tr>
<td>iNOS</td>
<td>Mouse</td>
<td>CTGTGGTTGATAGCAAGACATTT</td>
<td>ATGTGATGCAAAGACGCGAAAC</td>
<td>167</td>
</tr>
<tr>
<td>eNOS</td>
<td>Mouse</td>
<td>AGGACATGTTTTGTCTGGCGCGA</td>
<td>AAATTGCTCGTGGATGCGTTTCT</td>
<td>155</td>
</tr>
<tr>
<td>eNOS</td>
<td>Human</td>
<td>ATGTTGGTGTGACCCAGCAAATACCCA</td>
<td>TGTCCTGACGCTGTGGTTTGGTAT</td>
<td>145</td>
</tr>
<tr>
<td>eNOS</td>
<td>Mouse</td>
<td>TTGAAGGAAAGTGGCGCCAA</td>
<td>GGCCGACCTGACCGC</td>
<td>151</td>
</tr>
</tbody>
</table>

RPLO, ribosomal protein large, P0; TLR4, toll-like receptor 4; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase.

The addition of the human milk oligosaccharide 2′-fucosyllactose prevented the inhibition on mesenteric perfusion observed in experimental necrotising enterocolitis in newborn mice

In order to perform the experiments that HMO-2FL could protect against the development of NEC, we next turned our attention to the effects of HMO-2FL on the potential regulation of eNOS-mediated mesenteric perfusion in mice that underwent experimental NEC. To do so, we first assessed the degree of mesenteric perfusion in the mouse model of experimental NEC in the presence or absence of HMO-2FL supplementation to the formula. As shown in Fig. 4, the intestinal perfusion in mice that were FF was significantly reduced compared with breast-fed controls, consistent with our previous findings. Importantly, the addition of HMO-2FL restored perfusion to levels comparable with that of mice that were breast-fed on each day of the model, as observed in Fig. 4(a) and quantified in Fig. 4(b). The improvement in perfusion corresponded to a pink and healthy appearing intestine in breast-fed mice as compared with the dusky bowel seen in NEC, which was reversed in the presence of HMO-2FL towards a healthy, pink and perfused appearance. Taken together, these findings illustrate that HMO-2FL restores intestinal perfusion in NEC. We next sought to explore the potential mechanisms involved and focused on the effects of the vasodilatory molecule eNOS.

Human milk oligosaccharide 2′-fucosyllactose maintains the expression of endothelial nitric oxide synthase in necrotising enterocolitis, and thus restores intestinal perfusion in neonatal mice

Having now shown that HMO-2FL restores mesenteric perfusion in NEC, we next sought to investigate the possibility that HMO-2FL may affect the expression of eNOS. To do so, we assessed the expression of eNOS in the intestine of mice with and without NEC in the presence or absence of HMO-2FL. As shown in Fig. 4, the expression of eNOS in the intestine was significantly reduced in FF mice compared with breast-fed control mice, and this was restored after HMO-2FL induction (Fig. 4(c) and (d (i, ii))). The finding that HMO-2FL could restore the expression of eNOS in the newborn gut in the setting of NEC raises the intriguing possibility that perhaps the protection against NEC by HMO-2FL occurs via induction of eNOS expression. To assess this directly, we next utilised two approaches to inhibit eNOS – the use of pharmacological inhibitors and the use of eNOS knockout mice – and sought to determine whether HMO-2FL could still protect against NEC development under conditions of eNOS inhibition. As shown in Fig. 5, we next treated mice with eNOS inhibitors L-NIO dihydrochloride and DPI. Importantly, under conditions of eNOS inhibition (verification in the online Supplementary Fig. S1(a)),

- **Table 1. List of primers**

<table>
<thead>
<tr>
<th>Gene</th>
<th>Species</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
<th>Amplicon size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RPLO</td>
<td>Mouse/human</td>
<td>GCCGACCTGGAGACTCAACT</td>
<td>CCATCAGGCCACACGCTTC</td>
<td>143</td>
</tr>
<tr>
<td>IL-6</td>
<td>Mouse</td>
<td>GGCTAAGGACCAAGACCATCCAA</td>
<td>TCTGACCACATGTGGAGATGCAA</td>
<td>138</td>
</tr>
<tr>
<td>TLR4</td>
<td>Mouse</td>
<td>TTATTCAGAAGGGGTTTGGTG</td>
<td>CAGAGATTGGTCCTCCATT</td>
<td>186</td>
</tr>
<tr>
<td>IL-1β</td>
<td>Mouse</td>
<td>AGTGGTGTGACCCAGCAAATACCCA</td>
<td>TGTCCTGACGCTGTGGTTTCCCA</td>
<td>175</td>
</tr>
<tr>
<td>iNOS</td>
<td>Mouse</td>
<td>CTGTGGTTGATAGCAAGACATTT</td>
<td>ATGTGATGCAAAGACGCGAAAC</td>
<td>167</td>
</tr>
<tr>
<td>eNOS</td>
<td>Mouse</td>
<td>AGGACATGTTTTGTCTGGCGCGA</td>
<td>AAATTGCTCGTGGATGCGTTTCT</td>
<td>155</td>
</tr>
<tr>
<td>eNOS</td>
<td>Human</td>
<td>ATGTTGGTGTGACCCAGCAAATACCCA</td>
<td>TGTCCTGACGCTGTGGTTTGGTAT</td>
<td>145</td>
</tr>
<tr>
<td>eNOS</td>
<td>Mouse</td>
<td>TTGAAGGAAAGTGGCGCCAA</td>
<td>GGCCGACCTGACCGC</td>
<td>151</td>
</tr>
</tbody>
</table>

RPLO, ribosomal protein large, P0; TLR4, toll-like receptor 4; iNOS, inducible nitric oxide synthase; eNOS, endothelial nitric oxide synthase.
Fig. 1. The addition of the human milk oligosaccharide (HMO) 2’-fucosyllactose to infant formula attenuates necrotising enterocolitis (NEC) severity in newborn mice. (a) Representative gross images of the intestine from wild-type neonatal mice that were either breast-fed (BF) or induced to develop NEC in the absence or presence of HMO in their feeds. (b) Representative haematoxylin–eosin micrographs of the terminal ileum of wild-type mice that were either BF, breast-fed with daily administration of HMO (BF + HMO) or received NEC formula with or without the addition of HMO to their feeds (FF or FF + HMO). (c) Daily body weights (g) of experimental animals for the duration of the NEC model. BF, BF; BF + HMO; FF, FF; FF + HMO. (d) NEC severity score (0–3) assigned by a pathologist blinded to the study conditions and treatment groups. (e) The ratio of the measured mRNA expression of the pro-inflammatory genes within the intestine including inducible nitric oxide synthase (iNOS), IL-6, IL-1β and toll-like receptor 4 (TLR4) of the indicated groups relative to the housekeeping gene RPLO, as in the study by Good et al.122 * P < 0.05 v. BF control animals, ** P < 0.05 v. FF. Values are means with their standard errors. Scale bar is 50 μm. Representative of three separate experiments, where each mouse represents an individual symbol on a graph.
HMO-2′FL failed to protect against NEC as demonstrated by histology, the pro-inflammatory cytokine IL-1β and NEC severity score (Fig. 5(a) and (c)), revealing that HMO-2′FL acts in part via eNOS activity. To assess whether eNOS expression was required for the protection exerted by HMO-2′FL against NEC, we next performed studies in eNOS−/− mice (Fig. 6, online Supplementary Fig. S1(b)) and as shown in the study by Shesely et al. (49). As shown in Fig. 6, eNOS−/− mice were significantly vulnerable to experimental NEC, consistent with our previous studies (38), and administration of HMO-2′FL did not confer protection as demonstrated by a disruption in the intestinal mucosal architecture, increase in pro-inflammatory cytokines and NEC severity, as well as significantly reduced intestinal perfusion (Fig. 6(a) and (d)).
findings demonstrate that HMO-2′-FL is protective against experimental NEC in a manner that is dependent on the expression and function of eNOS.

**Lipopolysaccharide decreases the expression of endothelial nitric oxide synthase in HUVEC endothelial cells and this decrease is attenuated by human milk oligosaccharide 2′-fucosyllactose**

In the final series of studies, we sought to explore in greater detail the potential mechanisms by which HMO-2′-FL could regulate eNOS expression – and therefore mesenteric perfusion – in the newborn gut. To do so, we first examined whether HMO-2′-FL could regulate the mRNA expression of eNOS in HUVEC endothelial cells in the presence of either LPS as a TLR4 ligand or LPS in the presence of HMO-2′-FL to mimic the situation observed in the mesenteric endothelium. As shown in Fig. 7, TLR4 activation reduced the expression of eNOS mRNA in HUVEC (Fig. 7(a)), consistent with our previous findings in primary cultured endothelial cells. Importantly, the addition of HMO-2′-FL restored eNOS expression as demonstrated by immunocytochemistry (Fig. 7(b)), consistent with the intestinal protein expression shown in Fig. 4(d), and demonstrated a clear role of HMO-2′-FL in the regulation of eNOS gene expression and function.

**Discussion**

In the current study, we utilised an experimental mouse model of NEC, which recapitulates several of the features seen in premature infants with NEC, including gross evidence of small intestinal ischaemia, pneumatosis intestinalis and inflammation, as well as histological evidence of mucosal destruction, to demonstrate that the administration of formula containing an abundant HMO in human milk – namely, 2′FL – significantly reduces the severity of experimental NEC in newborn mice. In seeking to define the mechanisms involved, we and others have shown that TLR4 signalling in the gut leads to NEC via mucosal disruption, leading to LPS translocation and a loss of eNOS, which results in impaired perfusion and the development of intestinal ischaemia. We have now determined that HMO-2′-FL-supplemented formula acts by regulating the degree of blood flow to the newborn intestine via eNOS, and that this novel pathway may explain some of the previously unrecognised benefits of this breast milk oligosaccharide.

The current findings may shed light on the impact of other aspects of maternal breast milk production that could impact on the likelihood of NEC development to occur. Specifically, previous authors have noted that nearly 20% of women in the population are homozygous for common mutations in the secretor gene fucosyltransferase 2 (FUT2) and are unable to produce HMO-2′-FL, which has been shown to impact the intestinal microbiota of their infants. The studies on the relationship of FUT2 mutations and risk for NEC to date have focused predominantly on the phenotype or genotype of the baby rather than the mother. We now speculate that any increase in NEC in premature infants receiving milk from homozygous FUT2 mutant mothers may reflect a lack of endogenous 2′FL, suggesting that supplementing their milk with 2′FL could benefit their premature infants through NEC protection.

Our findings extend our knowledge on the mechanisms by which HMO act on the neonatal intestine, and provide additional insights into the benefit of breast milk that is observed in premature infants at risk for developing NEC. Specifically, the molecular details underlying the capacity of two genera of gut bacteria to consume HMO have been demonstrated, including Bifidobacterium and Bacteroides. Indeed, the presence of gram-negative bacteria including E. coli and Klebsiella has been associated with NEC outbreaks, and are commonly seen in the blood and stool of patients with this disease. HMO have also been shown to have structural homology to cell surface glycans, and can therefore act as molecular mimics, or decoys, by binding to luminal bacteria, and thereby prevent binding to the intestinal epithelium, thus potentially reducing the degree of bacterial inflammation and activation of toll-like receptors on the intestinal epithelium, which we have shown to be required for NEC development. Moreover, analysis of the microbiota revealed that supplementation of HMO-2′-FL to the experimental NEC formula increased the faecal content of Ruminococcaceae, a family of bacteria of class Clostridia, which typically increase in premature infants as they mature and approach 36 weeks of postconceptional age. Although HMO-2′-FL appears to affect the microbiota, these...
Fig. 4. Formula supplementation with the human milk oligosaccharide (HMO) 2′-fucosyllactose enhances mesenteric perfusion in experimental necrotising enterocolitis (NEC) via maintenance of intestinal endothelial nitric oxide synthase (eNOS) expression. (a) Representative confocal micrographs of terminal ileal whole mounts from wild-type neonatal mice from the indicated treatment groups: breast-fed controls (BF), breast-fed with HMO (BF + HMO, experimental NEC, formula fed (FF) and FF with HMO (FF + HMO), as well as mice that in addition to the experimental NEC model and HMO treatment also received the eNOS inhibitors N5-(1-iminoethyl)-L-ornithine dihydrochloride (L-NIO) (FF + HMO + L-NIO) or diphenyleneiodonium chloride (DPI) (FF + HMO + DPI) with their formula. After intracardiac injection with the fluorescent tracer tomato lectin, which correlates with intestinal blood flow (green), whole mounts were immunostained for platelet endothelial cell adhesion molecule 1 (PECAM-1) to assess the intestinal microvasculature (red). (b) Graph representing villus perfusion index as described in the Materials and methods section expressed as a percentage. (c) Intestinal eNOS mRNA expression by quantitative real-time PCR (qRT-PCR) in the indicated treatment groups relative to the housekeeping gene RPL0. (d) SDS-PAGE immunoprecipitation Western blot (IP-WB) performed on the terminal ileum of wild-type mice in the indicated treatment groups. IgG is shown as a loading control (i); densitometry quantification with Image J performed on three samples per group in (ii). * P < 0.05 v. breast-fed control animals, ** P < 0.05 v. FF. Values are means with their standard errors. Scale bar is 50 μm. Representative of at least three separate experiments, where each mouse represents an individual symbol on a graph.
changes do not seem to be the primary mechanism of protection against NEC. The current findings extend the studies by Goehring et al. who demonstrated that in addition to these local effects HMO are absorbed systemically in human infants, which in this case explains the effect on mesenteric perfusion through the activity of the vasodilator eNOS. Furthermore, 2′FL
has been demonstrated in the plasma of breast-fed infants, although in lesser abundance than several other HMO\(^{33}\), and in the urine of breast milk-fed premature infants\(^{59}\). Although our studies did not directly test the systemic absorption of 2\(\prime\)FL, other authors have elegantly shown that HMO are absorbed in the intestine and can be measured in the serum and urine of rats, demonstrating the significance of the effects of HMO on other species\(^{19,60}\). In determining which HMO are present in mouse breast milk, Prieto et al.\(^{61}\) have shown that 2\(\prime\)FL is not present in mouse milk, while 3\(\prime\)FL indeed is. Importantly, the biological significance of the differential expression of HMO in breast milk across various species is unknown. It is noteworthy that the current study is supported by previous studies by Jantscher-Krenn et al.\(^{19}\) who showed that the addition of the HMO disialyllacto-N-tetraose prevents NEC in neonatal rats. Although these studies did not provide a mechanism to explain these protective effects, and indeed the effects may be structure specific, we now speculate that the protection achieved was similar to that observed in the current study, and involved an enhanced mesenteric perfusion. Additional effects on the

---

**Fig. 6.** The human milk oligosaccharide (HMO) 2\(\prime\)-fucosyllactose does not protect against necrotising enterocolitis (NEC) or enhance intestinal perfusion in endothelial nitric oxide synthase (eNOS\(^{-/-}\)) mice. (a) Representative haematoxylin–eosin micrographs of the terminal ileum of eNOS\(^{-/-}\) mice in the indicated treatment groups. (b) Representative confocal micrographs of terminal ileal whole mounts from eNOS\(^{-/-}\) mice that received HMO and were either breast-fed (BF + HMO) or were formula-fed (FF + HMO). Whole mounts were stained for platelet endothelial cell adhesion molecule 1 (PECAM-1) to assess the microvasculature of the intestine and subjected to intra-cardiac injections with tomato lectin as a marker of intestinal perfusion (green). (c) Graph representing villus perfusion index as described in the Materials and methods section expressed as a percentage. (d) NEC severity score assessed by a pathologist blinded to the study conditions. (e) IL-1\(\beta\) mRNA expression from the terminal ileum of the mice in the indicated treatment groups. * P < 0.05 v. breast-fed control animals, ** P < 0.05 v. BF + HMO. Values are means with their standard errors. Scale bar is 50 \(\mu\)m. Representative of at least three separate experiments, where each mouse represents an individual symbol on a graph. qRT-PCR, quantitative real-time PCR.
microbiota and on bacterial enterocyte signalling may also play a role in the protection in these two studies, and additional work will be required to determine these precise effects. It is possible that 2′FL gets absorbed into the circulation, attenuates endothelial TLR4 signalling and subsequently maintains eNOS levels. Moreover, it is likely that breast milk has various direct TLR4 inhibitors, as we have recently identified a class of small molecule inhibitors of TLR4(62), which are themselves oligosaccharides, suggesting that HMO-2′FL itself may inhibit TLR4 signalling. In support of this possibility, the expression of TLR4 was reduced in the mucosa of mice after administration of HMO-2′FL. Furthermore, it has recently been reported that HMO-2′FL modulates the expression of cluster of differentiation 14 (CD14), a molecule that is essential for LPS binding and optimal TLR4 signalling(63). The current study thus advances our understanding of the mechanisms by which breast milk may protect against the development of NEC.

In summary, the current findings reveal an important role for HMO-2′FL in the protection against the development of NEC in newborn mice through the maintenance of mesenteric perfusion via a mechanism that requires the expression of eNOS. These findings expand our understanding about the protective benefits of breast milk for premature infants, in which HMO are present in high amounts, and also indicate that in addition to the established roles of HMO on the microbiota or on the epithelial surface, these molecules may have key roles when absorbed systemically. Although our preclinical studies were performed in neonatal mice rather than premature infants, the current studies also suggest that 2′FL is one of the components within human breast milk found to be protective against NEC, which remains an important goal of neonatal nutrition research. Furthermore, these studies reinforce the statements by the American Academy of Pediatrics Section on Breastfeeding and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition that the preferred feeding for premature infants should be the mother’s own milk with donor human milk from an established human milk bank as a second choice if the mother’s milk supply is inadequate(64,65).

![Graph showing expression of endothelial nitric oxide synthase (eNOS) enhanced by HMO-2′-fucosyllactose in HUVEC](image)

**Fig. 7.** Expression of endothelial nitric oxide synthase (eNOS) is enhanced by the human milk oligosaccharide (HMO) 2′-fucosyllactose in HUVEC-C (HUVEC). (a) eNOS mRNA by quantitative real-time PCR (qRT-PCR) from HUVEC in the indicated treatment groups: vehicle control (Ctrl), lipopolysaccharide (LPS), HMO alone (HMO) and LPS with HMO (LPS + HMO) relative to the housekeeping gene RPLP0. (b) Representative confocal micrographs of HUVEC with the indicated treatment groups stained for eNOS (red) and 4,6-diamidino-2-phenylindole, dihydrochloride (DAPI) (blue). * P < 0.05 v. vehicle control, ** P < 0.05 v. LPS. Values are means with their standard errors. Scale bar is 10 μm. Results representative of three separate experiments with over 50 high power fields per group imaged.
Acknowledgements

M. G. is supported by K08DK101608 from the National Institutes of Health and the Children’s Hospital of Pittsburgh of the UPMC Health System. D. J. H. is supported by a sponsored research grant from Abbott Nutrition, as well as R01DK083752 and R01GM078238 from the National Institutes of Health.

M. G., C. P. S., R. H. B., K. C. G. and D. J. H. designed and/or performed experiments, analysed results, wrote and edited the manuscript; Y. Y., H. J., P. L., W. B. F., L. Y. M., T. P., D. F. N., Q. Z. and C. M. performed experiments and analysed data.

The authors declare that there are no conflicts of interest.

Supplementary material

For supplementary material/s referred to in this article, please visit http://dx.doi.org/10.1017/S0007114516002944

References

2-Fucosyllactose enhances gut perfusion

1187


